Institutionelle Behandlungsvolumen und Therapiequalität der I‑125-Seed-Implantation beim Prostatakarzinom in einer japanweiten prospektiven Kohortenstudie

Translated title of the contribution: Institutional patient accrual volume and the treatment quality of I‑125 prostate seed implantation in a Japanese nationwide prospective cohort study

Katsumasa Nakamura, Saiji Ohga, Atsunori Yorozu, Shiro Saito, Takashi Kikuchi, Takushi Dokiya, Masanori Fukushima, Hidetoshi Yamanaka

Research output: Contribution to journalArticle

Abstract

Purpose: It is unclear whether experience at high-volume institute improves the treatment quality of prostate seed implantation. The aim of this study was to evaluate the effect of institutional experience on postimplant dosimetric parameters in a nationwide prospective cohort study. Methods: From July 2005 to June 2007, 2354 patients were registered in the Japanese Prostate Cancer Outcome Study of Permanent I‑125 Seed Implantation (J-POPS), and 1126 patients treated with seed implantation alone were evaluated. As a surrogate for institutional experience, we classified the J‑POPS institutions as high-volume (patient accrual volume was ≥120 patients per institution) or low-volume institutions (patient accrual volume was <120 patients per institution). To compare treatment quality between institutions, we evaluated the postimplant dosimetric parameters including D90, V100/150 (prostatic dose parameters), UD5/90, U200 (urethral dose parameters), and rectum R100/150 (rectal dose parameters). Results: In the 5 high-volume institutions (n = 601 patients), most of the patients were treated with >144 Gy of D90, whereas in the 20 low-volume institutions (n = 525) some of the patients were treated with <144 Gy. The V100 of most of the high-volume institution patients were >90%, whereas in the low-volume institutions a considerable percentage of patients showed lower V100. Although there was no correlation between D90 and rectal dose parameters, UD90 had a moderate positive correlation with D90 in both the high- and low-volume institutions. U200 varied more widely in the low-volume institutions. Conclusions: Our findings indicate that the institutional patient accrual volume is associated with the treatment quality of I‑125 prostate seed implantation.

Original languageGerman
Pages (from-to)412-419
Number of pages8
JournalStrahlentherapie und Onkologie
Volume195
Issue number5
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Prostate
Seeds
Cohort Studies
Prospective Studies
Therapeutics
Prostatic Neoplasms
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Institutionelle Behandlungsvolumen und Therapiequalität der I‑125-Seed-Implantation beim Prostatakarzinom in einer japanweiten prospektiven Kohortenstudie. / Nakamura, Katsumasa; Ohga, Saiji; Yorozu, Atsunori; Saito, Shiro; Kikuchi, Takashi; Dokiya, Takushi; Fukushima, Masanori; Yamanaka, Hidetoshi.

In: Strahlentherapie und Onkologie, Vol. 195, No. 5, 01.05.2019, p. 412-419.

Research output: Contribution to journalArticle

Nakamura, Katsumasa ; Ohga, Saiji ; Yorozu, Atsunori ; Saito, Shiro ; Kikuchi, Takashi ; Dokiya, Takushi ; Fukushima, Masanori ; Yamanaka, Hidetoshi. / Institutionelle Behandlungsvolumen und Therapiequalität der I‑125-Seed-Implantation beim Prostatakarzinom in einer japanweiten prospektiven Kohortenstudie. In: Strahlentherapie und Onkologie. 2019 ; Vol. 195, No. 5. pp. 412-419.
@article{edaec142563840bcb0dbae0578fa0886,
title = "Institutionelle Behandlungsvolumen und Therapiequalit{\"a}t der I‑125-Seed-Implantation beim Prostatakarzinom in einer japanweiten prospektiven Kohortenstudie",
abstract = "Purpose: It is unclear whether experience at high-volume institute improves the treatment quality of prostate seed implantation. The aim of this study was to evaluate the effect of institutional experience on postimplant dosimetric parameters in a nationwide prospective cohort study. Methods: From July 2005 to June 2007, 2354 patients were registered in the Japanese Prostate Cancer Outcome Study of Permanent I‑125 Seed Implantation (J-POPS), and 1126 patients treated with seed implantation alone were evaluated. As a surrogate for institutional experience, we classified the J‑POPS institutions as high-volume (patient accrual volume was ≥120 patients per institution) or low-volume institutions (patient accrual volume was <120 patients per institution). To compare treatment quality between institutions, we evaluated the postimplant dosimetric parameters including D90, V100/150 (prostatic dose parameters), UD5/90, U200 (urethral dose parameters), and rectum R100/150 (rectal dose parameters). Results: In the 5 high-volume institutions (n = 601 patients), most of the patients were treated with >144 Gy of D90, whereas in the 20 low-volume institutions (n = 525) some of the patients were treated with <144 Gy. The V100 of most of the high-volume institution patients were >90{\%}, whereas in the low-volume institutions a considerable percentage of patients showed lower V100. Although there was no correlation between D90 and rectal dose parameters, UD90 had a moderate positive correlation with D90 in both the high- and low-volume institutions. U200 varied more widely in the low-volume institutions. Conclusions: Our findings indicate that the institutional patient accrual volume is associated with the treatment quality of I‑125 prostate seed implantation.",
author = "Katsumasa Nakamura and Saiji Ohga and Atsunori Yorozu and Shiro Saito and Takashi Kikuchi and Takushi Dokiya and Masanori Fukushima and Hidetoshi Yamanaka",
year = "2019",
month = "5",
day = "1",
doi = "10.1007/s00066-018-1407-y",
language = "ドイツ語",
volume = "195",
pages = "412--419",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "5",

}

TY - JOUR

T1 - Institutionelle Behandlungsvolumen und Therapiequalität der I‑125-Seed-Implantation beim Prostatakarzinom in einer japanweiten prospektiven Kohortenstudie

AU - Nakamura, Katsumasa

AU - Ohga, Saiji

AU - Yorozu, Atsunori

AU - Saito, Shiro

AU - Kikuchi, Takashi

AU - Dokiya, Takushi

AU - Fukushima, Masanori

AU - Yamanaka, Hidetoshi

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Purpose: It is unclear whether experience at high-volume institute improves the treatment quality of prostate seed implantation. The aim of this study was to evaluate the effect of institutional experience on postimplant dosimetric parameters in a nationwide prospective cohort study. Methods: From July 2005 to June 2007, 2354 patients were registered in the Japanese Prostate Cancer Outcome Study of Permanent I‑125 Seed Implantation (J-POPS), and 1126 patients treated with seed implantation alone were evaluated. As a surrogate for institutional experience, we classified the J‑POPS institutions as high-volume (patient accrual volume was ≥120 patients per institution) or low-volume institutions (patient accrual volume was <120 patients per institution). To compare treatment quality between institutions, we evaluated the postimplant dosimetric parameters including D90, V100/150 (prostatic dose parameters), UD5/90, U200 (urethral dose parameters), and rectum R100/150 (rectal dose parameters). Results: In the 5 high-volume institutions (n = 601 patients), most of the patients were treated with >144 Gy of D90, whereas in the 20 low-volume institutions (n = 525) some of the patients were treated with <144 Gy. The V100 of most of the high-volume institution patients were >90%, whereas in the low-volume institutions a considerable percentage of patients showed lower V100. Although there was no correlation between D90 and rectal dose parameters, UD90 had a moderate positive correlation with D90 in both the high- and low-volume institutions. U200 varied more widely in the low-volume institutions. Conclusions: Our findings indicate that the institutional patient accrual volume is associated with the treatment quality of I‑125 prostate seed implantation.

AB - Purpose: It is unclear whether experience at high-volume institute improves the treatment quality of prostate seed implantation. The aim of this study was to evaluate the effect of institutional experience on postimplant dosimetric parameters in a nationwide prospective cohort study. Methods: From July 2005 to June 2007, 2354 patients were registered in the Japanese Prostate Cancer Outcome Study of Permanent I‑125 Seed Implantation (J-POPS), and 1126 patients treated with seed implantation alone were evaluated. As a surrogate for institutional experience, we classified the J‑POPS institutions as high-volume (patient accrual volume was ≥120 patients per institution) or low-volume institutions (patient accrual volume was <120 patients per institution). To compare treatment quality between institutions, we evaluated the postimplant dosimetric parameters including D90, V100/150 (prostatic dose parameters), UD5/90, U200 (urethral dose parameters), and rectum R100/150 (rectal dose parameters). Results: In the 5 high-volume institutions (n = 601 patients), most of the patients were treated with >144 Gy of D90, whereas in the 20 low-volume institutions (n = 525) some of the patients were treated with <144 Gy. The V100 of most of the high-volume institution patients were >90%, whereas in the low-volume institutions a considerable percentage of patients showed lower V100. Although there was no correlation between D90 and rectal dose parameters, UD90 had a moderate positive correlation with D90 in both the high- and low-volume institutions. U200 varied more widely in the low-volume institutions. Conclusions: Our findings indicate that the institutional patient accrual volume is associated with the treatment quality of I‑125 prostate seed implantation.

UR - http://www.scopus.com/inward/record.url?scp=85057757858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057757858&partnerID=8YFLogxK

U2 - 10.1007/s00066-018-1407-y

DO - 10.1007/s00066-018-1407-y

M3 - 記事

AN - SCOPUS:85057757858

VL - 195

SP - 412

EP - 419

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 5

ER -